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Study of the deleterious effect of genetic variants in disease genes is usually focused 
on the predicted effect on protein function. However, previous findings indicated that the 
disruption of the splicing process represent an important ethiopathogenic mechanism 
in Hereditary Breast Ovarian Cancer (HBOC). Nearly 200 different sequence variants of 
the BRCA genes have been identified in breast/ovarian cancer patients of the Prevention 
Programme of Castilla y León (Spain). A new mutation of the acceptor splice site of 
BRCA2 exon 20 (c.8488-1G>A) was detected in a breast cancer patient of the Genetic 
Counselling Unit of Castilla y León.
In order to investigate the effect of c.8488-1G>A on splicing and the splicing regulatory 
mechanisms, we performed bioinformatic analysis (NNSPLICE, ESEfinder and ESRsearch) 
together with splicing functional assays of this variant and all the mutations described 
in the BIC database of BRCA2 exons 19 and 20. Based on the creation/disruption of 
putative enhancers/silencers and disruption of the natural splice sites, we selected 16 
of 77 BIC variants. We also created five novel variants (no detected in patients) that 
affected highly conserved Splicing Regulatory Elements (SREs). Moreover, by comparing 
human BRCA2 intron 19 ( bp)with six different species, we found that human intron 
19 contained an Alu sequence. In addition flanking regions to the Alu element were 
highly conserved. We therefore generated 2 deletions of the conserved sequences and a 
deletion of 272pb of the Alu sequence to test their roles in splicing. 
Variant c.8488-1G>A was assayed by RT-PCR of patient lymphocyte mRNA and hybrid 
minigene experiments in HeLa cells. The rest of the variants were generated by direct 
mutagenesis of the wild type minigene of BRCA2 ivs18-exon19-ivs19-exon20-ivs20. 
Functional assays showed that 8 variants altered the splicing process by different 
mechanisms, indicating that any DNA change can disrupt it. Four variants disrupted the 
canonical splice sites (c.8488-1G>A; c.8488-2A>G; c.8487+1G>A; c.8487+3A>G) and 
were associated with total skipping of their exons; and two affected splicing enhancers/
silencers (missense c.8378G>A and c.8609A>G+c.8611G>T) that caused partial 
splicing effects. Finally, it cannot be elucidated if missense c.8486A>T caused aberrant 
splicing due to the disruption either of the donor site of exon 19 or SREs (enhancer or 
silencer motifs). Neither of the deletions of the conserved intronic motifs had any splicing 
consequence. However, the elimination of the Alu sequence totally altered splicing of 
exons 19 and 20, suggesting a relevant role for constitutive splicing in humans.
In conclusion, aberrant splicing represent a relevant pathogenic mechanism in hereditary 
breast/ovarian cancer, and further study of these splicing defects may increase the 
proportion of families that benefit from genetic counselling. Splicing functional assays are 
valuable tools to discriminate between benign polymorphisms and pathogenic variants.
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